logo-loader
RNS
Kromek Group PLC

Result of AGM

RNS Number : 2844A
Kromek Group PLC
23 October 2026
 

23 October 2026

 

Kromek Group plc 

(“Kromek” or the “Group”) 

 

Result of AGM

 

Kromek (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announces that at its annual general meeting (“AGM”), held earlier today, all resolutions were duly passed.

 

Details of the proxy voting results, which should be read alongside the Notice of AGM, are below:

 

Resolution

Votes for*

Votes against

Votes withheld

Total proxy votes

 

No. of votes

% of votes cast**

No. of votes

% of votes cast**

No. of votes

 

1

205,022,327

99.61

796,215

0.39

2,843,040

208,661,582

2

204,417,129

99.10

1,860,846

0.90

2,383,607

208,661,582

3

203,475,996

98.64

2,804,385

1.36

2,381,201

208,661,582

4

203,745,706

98.67

2,751,896

1.33

2,163,980

208,661,582

5

202,889,975

98.37

3,355,583

1.63

2,416,024

208,661,582

6

201,047,402

97.83

4,462,081

2.17

3,152,099

208,661,582

7

201,576,283

98.09

3,920,647

1.91

3,164,652

208,661,582

8

205,402,636

99.37

1,300,513

0.63

1,958,433

208,661,582

9

202,294,735

98.93

2,194,665

1.07

4,172,182

208,661,582

*Includes discretionary votes

**Excludes withheld votes

 

 

Enquiries 

 

Investor questions on this announcement

 

We encourage all investors to share questions on this announcement via our investor hub

https://investors.kromek.com/link/r8XkWr  

 

 

Kromek Group plc 

 

Arnab Basu, CEO 

Claire Burgess, CFO 

+44 (0)1740 626 060 

 

 

Cavendish Capital Markets Limited (Nominated Adviser and Broker)  

  

Geoff Nash/Giles Balleny/Seamus Fricker – Corporate Finance 

Andrew Burdis – ECM

Michael Johnson – Sales

+44 (0)20 7220 0500 

 

 

 

Gracechurch Group (Financial PR) 

 

Harry Chathli/Claire Norbury

+44 (0)20 4582 3500 

 

Engage with the Kromek management team directly by asking questions, watching video
summaries and seeing what other shareholders have to say. Navigate to our interactive investor
hub here: https://investors.kromek.com/

 

Subscribe to our news alert service: https://investors.kromek.com/auth/signup

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGEAFEDAFAKFFA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read